top of page

HELP 4 HD INTERNATIONAL

Stand Up Speak Up 4 HD 🎉 Click Here

Search

uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy

katie8288

Jun 23, 2022

0 min read

Recent Posts

Prilenia Appoints Frederick (Rick) Munschauer, MD, FAAN, as Chief Medical Officer

Prilenia Appoints Frederick (Rick) Munschauer, MD, FAAN, as Chief Medical Officer

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease

What is the Difference Between CBER and CDER at the FDA?

What is the Difference Between CBER and CDER at the FDA?

Comments

bottom of page